Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, et al
Later in the protocol, you burn through vials rapidly and need consistent supply
Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the liraflame randomized placebo-controlled trial
Never switch medications without professional guidance
References: IQVIA LAAD pharmacy claims data, US Market Access Strategy Consulting analysis Eli Lilly Tightens Access to Diabetes Drug, Frustrating Some People with Obesity, STAT News New Demand in an Old Market Read part 2 of this blog series to learn how the launch of Mounjaro transformed the GLP-1 market and led to the emergence of a new type of patient access profile thats challenging todays traditional diabetes care paradigm
Chronic Use: Unlike short-course therapies, GLP-1 agents are used chronically